Selling Into Pharma Clinical Ops: The Study Is Already Behind, and That's Your Opening

The clock everyone in the room is watching

Every clinical operations leader I have ever spoken to is behind. Not because they are bad at the job. Because the plan assumed sites would activate on time, patients would show up, and the protocol would survive contact with reality. None of those three things happen together.

That is your opening, and it is also the trap. The opening is that a slipped timeline is the most expensive thing in their world, far more expensive than whatever you are selling. The trap is that knowing this makes sellers loud. They walk in swinging urgency at a buyer who has been living inside that urgency for eighteen months and does not need a stranger to explain it to them.

So the job when selling to clinical operations in pharma is not to create urgency. It already exists, at a pressure you cannot manufacture. The job is to attach yourself to a specific point of failure in a specific study, in language the room recognizes, without pretending you went to medical school.

I have sold inside AWS and Dell and I have built and exited four businesses, and I will say plainly that this is one of the harder buying environments I have worked around. Not because the people are difficult. They are usually generous. It is because the thing that makes them move fast operationally is the same thing that makes them move slowly commercially: a study is a regulated object, and everything you touch near it inherits that.

The study lifecycle, in the version a seller actually needs

You do not need to understand clinical development. You need to understand where the money, the panic, and the decision rights sit at each stage.

Protocol design and startup. The protocol is the document that governs everything — who qualifies, what gets measured, how often patients come in. It is written largely by clinical development and medical, not by the ops people who will have to run it. By the time Clinical Ops sees it, the inclusion and exclusion criteria that will strangle enrollment are already written down. This is where feasibility work happens: which countries, which sites, how many. If you sell anything that touches feasibility or site selection, this is your window, and it closes early.

Site activation. Contracts, budgets, ethics committee and IRB submissions, regulatory packages, site initiation visits. This is unglamorous, entirely administrative, and one of the most reliable places a timeline dies. A site that takes months longer than planned to activate does not make that time back. Sellers underrate this stage because it sounds like paperwork. Clinical Ops does not underrate it. Ask a study manager about contracting cycle times and watch the temperature change.

Enrollment. The stage everyone means when they say the study is behind. First patient in, last patient in, and the gap between the two versus what the plan said. Screen failure — patients who come in, get assessed, and turn out not to qualify — quietly eats the budget and the schedule at the same time, because you paid for the visit either way. Sites that were supposed to deliver a steady flow enroll one patient and go dark. Ops spends its week deciding whether to add sites, add countries, or amend the protocol.

Conduct and close-out. Monitoring, data cleaning, query resolution, database lock. Less dramatic, but this is where a lot of software actually lives, and where the pain is chronic rather than acute. Chronic pain is a harder sale. It does not have a date attached to it.

Running underneath all of it: the protocol amendment. When the protocol changes, ethics submissions reopen, site training repeats, informed consent gets redone, and every system that encoded the old protocol has to encode the new one. When a Clinical Ops person tells you an amendment is coming, they are telling you their next quarter is gone. If your product makes amendments cheaper to absorb, say so in those words, because that is a wound they can feel.

Who owns what, and why your champion cannot sign

The org chart here is not a chart. It is a negotiation between four parties who do not report to each other.

Clinical Operations inside the sponsor owns delivery of the study. Study managers, clinical trial managers, a head of Clinical Ops or clinical development operations above them. They feel the timeline most directly. They are also, frequently, the least empowered to buy, because their budget is study budget and study budget was set before you arrived.

The CRO is the contract research organization actually running large parts of the operation. Sometimes they run nearly all of it. If the sponsor has outsourced delivery, your product may have to be adopted by an organization that is not your customer, was not consulted, and has its own preferred tooling. I have watched deals stall for a full quarter because nobody asked early enough whether the CRO would have to touch the thing. Ask on the first call. It is not a rude question.

The sites — hospitals, academic centers, private research clinics — are where patients actually are. They are not the sponsor's employees. They are running your study alongside other sponsors' studies and their normal clinical load. Anything you add to their day is a cost you are imposing on people who can simply decline to comply. Hold that thought.

Medical Affairs is a separate world with adjacent problems. Field medical, MSLs, medical information, publications, congress activity, investigator relationships. They care about scientific exchange and about the relationship with key investigators — some of whom are the same physicians running your trial sites. They are typically evaluated on the quality of engagement, not enrollment. If you sell to both, do not use one deck. The words that land with a study manager sound commercial and slightly grubby to a medical director, and there are compliance reasons for that instinct, not just taste.

And then procurement, IT, quality assurance, data privacy, and information security. None of them want your product. All of them can stop it.

Site burden is the objection under most polite nos

Here is the single most useful thing I can hand you.

When a Clinical Ops buyer says "this is interesting, let us revisit next study," the thought behind it is usually not budget and usually not skepticism about your value. It is: I cannot ask my sites to do one more thing.

Sites are the scarce resource. A good investigator with the right patient population and a coordinator who answers email is worth protecting. Sponsors compete for them. If your tool requires the site coordinator to log into another portal, learn another interface, or enter data twice, you are asking Clinical Ops to spend relationship capital they were saving for something else — like asking the site to enroll faster, or to accept the amendment that is coming.

So surface it yourself. Early, out loud, before they have to raise it: "Walk me through what this asks of the site. If the answer is another login, tell me now, because that changes whether this is worth your time." If your product genuinely reduces site burden, that is the headline, above every efficiency claim you were going to lead with. If it adds burden and buys something else in exchange, name the trade honestly. Clinical Ops people are used to trades. They are not used to vendors admitting one exists.

Talking about enrollment without pretending to be a clinician

You will be tempted to learn twelve pieces of vocabulary and deploy them. Do not. The room can tell instantly, and the recovery is ugly.

What works is using the operational language correctly and staying out of the science entirely. You can say enrollment rate, screen failure, site activation, protocol amendment, first patient in, database lock. You can ask how many sites are activated versus planned and how that compares to where they expected to be. Those are operational facts, and asking about them signals you have talked to people like them before.

What you cannot do is have an opinion about the therapeutic area. Do not speculate about why oncology enrollment is hard in a given indication. Do not offer a view on the endpoint. The moment you cross from operations into medicine, you are a salesperson pretending, and a room full of scientists will file you accordingly.

The honest frame is: "I do not know your therapeutic area. I know what breaks in study delivery, and I want to find out whether the thing that is breaking for you is the thing we fix." That sentence has opened more doors for me than any amount of borrowed jargon.

Validation, GxP, and the implementation promise you should stop making

Here is where a lot of otherwise good sellers write a cheque their delivery team cannot cash.

Systems that touch regulated clinical data live under Good Clinical Practice and, in the US, under the electronic records and signatures rule commonly called 21 CFR Part 11. In practice that means computer system validation: documented evidence that the system does what it is specified to do, with change control, audit trails, access controls, and a paper trail for all of it. Your customer's quality organization will want validation documentation. They may want to audit you. They will certainly want to know what happens to the validated state when you ship a release.

Two consequences for how you sell.

First, stop promising fast implementation as your differentiator. If the system is in scope for validation, the timeline is governed by their QA process, not your onboarding team. Promising a rapid go-live and then discovering validation adds months is how you lose credibility in the first ninety days of a relationship you spent nine months earning. Instead, say: "Implementation on our side is short. What usually sets the date is your validation process. Who owns that here, and have they seen a system like ours before?" That question makes you sound like someone who has done this.

Second, get the security and quality questionnaire early rather than late. It is coming regardless. A deal I have seen many times over: everything sails through, the champion is thrilled, and then a vendor assessment lands in week fourteen and the answers are not ready. Ask on the discovery call which assessments apply and what has held up other vendors. Your champion usually knows and is usually relieved you asked.

Sizing against one study versus the portfolio

There are two deals available to you and they are shaped very differently.

The single study deal is easier to start. It has a named owner, a live problem, and sometimes a study budget that can absorb it. It is smaller, it is often treated as a pilot whether or not anyone uses that word, and it ends when the study ends. The risk is that you build your entire relationship inside one trial and the trial finishes, the team disperses, and your renewal has no home.

The portfolio deal — the standard, across studies, across therapeutic areas — is where the real money is and where the buying committee triples in size. Now you have enterprise IT, a global process owner, a quality organization, procurement, and an internal politics problem about whose budget it lives in. Sales cycles stretch accordingly.

The move I would make almost every time: sell the single study, but structure it so it can become the portfolio. That means agreeing at the outset what "it worked" looks like in numbers the sponsor already tracks, not numbers you invented — activation timelines, enrollment against plan, whatever their study dashboard already reports. It means getting a process owner into the room even if they are not the buyer. And it means treating the study check-in as the commercial moment it is, which is exactly how a routine study review becomes an expansion conversation rather than a status update everyone forgets.

What the first thirty seconds sound like

Cold outreach into Clinical Ops fails for a boring reason: it leads with the product. A study manager who picks up is mid-crisis and gives you one sentence to prove you know what their week looks like.

So the opener names the operational reality, not the software. Something like: "I know you did not plan to take this call. I work with clinical ops teams on site activation timelines. If activation is not your problem right now, tell me and I will get off the phone." That last clause matters more than the rest of it. Giving someone a fast exit is what earns the extra twenty seconds. I have written out the longer version of this, including how it shifts for field medical leaders who are not running studies at all, in the pharma cold call script.

One warning. Do not name a specific molecule or trial you found on a registry and imply you know their program. It reads as surveillance, and in an industry this careful about information, that is a fast way to be remembered badly.

The twenty-five minute diagnosis

Discovery here is a triage, not a survey. In twenty-five minutes you need four things: which stage of which study is actually hurting, whether a CRO sits between the sponsor and the work, what the system would ask of sites, and who owns validation and vendor assessment.

Everything else can wait. Most sellers spend the whole call establishing pain they already knew existed and never ask a single question about the CRO or the quality process, then wonder why the deal dies in legal. The sequencing and the actual wording is what I laid out in the pharma discovery call guide, but even if you never read it, ask those four things and you will be ahead of the field.

Ask also what they will have to defend internally. Your champion is going to walk into a room and be asked why this and why now. If you have not given them the sentence they need, they will make one up, and it will be weaker than yours.

The demo, where the room's job is to break it

Understand what you are walking into. In most software demos, the audience is trying to imagine success. In pharma clinical ops, a serious room is trying to find the failure mode. That is not hostility. That is professional competence, in an industry where systems failing has consequences that are not commercial.

So do not demo the happy path. Demo the edge. Show what happens when the protocol amends mid-study. Show the audit trail. Show what a site coordinator sees on their worst day. When someone asks a question you cannot answer, say you cannot answer it and write it down — an honest "I do not know, I will find out by Thursday" costs you nothing here and a bluffed answer costs you the deal, because there is someone in that room who knows the real answer. That posture, plus a demo built around the questions the room is already forming, is the whole argument of the demo script for clinical operations buyers.

And let the quality person talk. They are often silent for forty minutes and then ask the one question that determines the outcome. Get to them earlier by inviting it: "Before we go further, is there anything from a validation or data integrity standpoint that would make this a non-starter?"

What I would do next

If I were picking up this territory tomorrow, I would spend the first week learning the operational vocabulary cold and the science not at all, then I would rehearse the four hardest objections out loud until the site burden answer came out in one clean sentence. That last part is what most reps skip. Reading a script is not rehearsal. Saying it badly, hearing it back, and saying it again is — and that is exactly what we built DrillCall for, so you can burn the awkward reps on a simulation instead of on a study manager who was never going to give you a second call.

The study is already behind. You cannot fix that. What you can do is show up sounding like someone who understands why, and who is not going to make their week worse.